Hyrimoz® (adalimumab-adaz) high-concentration formulation (HCF) biosimilar offers US patients reduced injection volume in citrate-free formulation A...
Thermo Fisher Scientific, a global leading company in science services, today announced the launch of the Gibco™ OncoPro™ tumor media kit. *, t...
New data demonstrates the ability of TLX250-CDx to detect extrarenal lesions, supporting potential clinical utility in the metastatic or recurrent setting,...
Enveric to expand existing manufacturing agreement with CDMO partner for enhanced supply of non-GMP and GMP EB-373 drug substance Enveric Biosciences (NAS...
-Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon ...
CAMZYOS is the first and only cardiac myosin inhibitor approved in the European Union Approval based on two positive Phase 3 trials, EXPLORER-HCM and VALO...
- Gilead Sciences K.K. is Now Marketing Authorization Holder -- -- Kite Cell Therapy Business Unit of Gilead Sciences K.K. will manage the product’s...
Yposkesi, SK pharmteco's clinical and commercial viral vector manufacturing subsidiary for Cell and Gene Therapy (C>), completes i...
Biopharma’s own leaders express a declining sense of industry resilience in the latest wide-reaching survey from Cytiva. The Global Biopharma Resilie...
“We are pleased to announce this strategic partnership with the government of Bangladesh, which demonstrates the company’s continued ability to...
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precis...
Pivotal study showed durable responses, with a 56% overall response rate, a 43% complete response (remission) rate and a median duration of response of 1...
– Stock for stock transaction valued at up to $65 million, an approximate three-fold premium over Surface’s anticipated net cash of $20 to $25 ...
Acquisition delivers industry-leading research capability, and strengthens pipeline with a novel candidate for ulcerative colitis, Crohn’s disease an...
© 2025 Biopharma Boardroom. All Rights Reserved.
